Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Assessment of Vitiligo Lesions Using Polarized Dermoscopy, Sub-Ultraviolet Reflectance Dermoscopy, and Ultraviolet Dermoscopy

28 de setembro de 2026 atualizado por: Sueda Sanli Arikan, Istanbul Training and Research Hospital

Evaluation of Morphological Findings Related to Activity, Stability, and Repigmentation in Vitiligo Lesions Using Polarized Dermoscopy, Sub-Ultraviolet Reflectance Dermoscopy, and Ultraviolet Fluorescence Dermoscopy: A Cross-Sectional Observational Imaging Study

The goal of this observational study is to learn how different close-up skin imaging methods show vitiligo spots in adults with vitiligo. The study will look at skin changes that may be related to whether a vitiligo spot is active, stable, or gaining color again.

The main question it aims to answer is: Can special light-based imaging methods show useful details of vitiligo spots differently than regular polarized dermoscopy?

Participants will have vitiligo spots photographed during one study visit. Researchers will take images using polarized dermoscopy, sub-ultraviolet reflectance imaging, and ultraviolet fluorescence dermoscopy. Dermatologists will later review the coded images and score how clearly selected skin features can be seen.

The study will not change participants' treatment. It will not include blood tests, biopsy, injections, or any other invasive procedure.

Visão geral do estudo

Status

Recrutamento

Condições

Descrição detalhada

This is a single-center, cross-sectional observational imaging study in patients with clinically diagnosed vitiligo.

During a single study visit, demographic and clinical information will be recorded, including disease duration, recent disease course, current treatment status, and patient-reported changes in selected lesions. One to three clinically suitable vitiligo lesions will be included in the main assessment dataset for each participant. Genital lesions will not be evaluated due to practical imaging limitations, hygiene considerations, and participant comfort.

Each selected lesion will be imaged using the Casio DZ-D100-AEA device, which allows simultaneous acquisition of digital contact polarized dermoscopy, digital contact non-polarized dermoscopy, and sub-ultraviolet reflectance dermoscopy images from the same lesion area with a single image capture. This approach is intended to improve within-lesion comparability between polarized dermoscopy and sub-ultraviolet reflectance dermoscopy. Non-polarized images will be obtained as an automatic device output but will not be included in the routine analysis. Ultraviolet fluorescence dermoscopy images will be obtained from the same selected lesion using the DermLite DL5 handheld ultraviolet dermoscope with a smartphone adapter.

For each participant, one lesion will be designated as the index lesion for the primary analysis. If available, the second and third lesions in the main assessment dataset may be used for secondary and exploratory analyses. In participants with more than three imaged lesions, additional lesion images beyond the lesions retained in the main assessment dataset will be assigned to a separate exploratory/calibration image pool and will not be included in the formal main assessment dataset.

The allocation of lesions to the main assessment dataset or the exploratory/calibration pool will be completed before formal image scoring. When more than three lesions are available from a participant, lesions with clearer recent clinical history regarding activity, stability, or repigmentation will be preferentially retained in the main assessment dataset. If several lesions have similarly clear clinical information, allocation will aim to preserve representation of active/progressive, stable, and repigmented/regressive lesions when possible.

The exploratory/calibration image pool will be used for initial exploratory review, refinement of morphological terminology, preparation of evaluator training material, and calibration of scoring rules. These images will not be used as confirmatory evidence for the primary analysis.

Morphological assessment items will be developed from the literature and refined through the calibration process. This process will be used to standardize terminology and scoring rules among dermatologist evaluators before formal image evaluation.

After the scoring form is finalized, coded images from the main assessment dataset will be evaluated by dermatologist evaluators using a 0-3 visibility scoring system. To reduce observer bias, images will be presented without participant identity, lesion code, clinical lesion category, treatment information, or clinical history.

Complete blinding to imaging modality may not be possible because the imaging modalities have characteristic color and light features. This will be considered a methodological limitation. However, the coded and randomized image review process is intended to reduce recognition bias, recall bias, and assessment-order bias.

Tipo de estudo

Observacional

Inscrição (Estimado)

100

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Contato de estudo

  • Nome: Sueda Şanlı Arıkan, Dermatology Resident Physician
  • Número de telefone: +90 5362483355
  • E-mail: sueda.sanli.md@gmail.com

Locais de estudo

      • Istanbul, Turquia (Türkiye)
        • Recrutamento
        • University of Health Sciences Istanbul Training and Research Hospital

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

18 anos e mais velhos (Adulto, Adulto mais velho)

Aceita Voluntários Saudáveis

Não

Gêneros Elegíveis para o Estudo

Tudo

Método de amostragem

Amostra Não Probabilística

População do estudo

Adult patients with clinically diagnosed vitiligo who attend the dermatology outpatient clinic and have at least one clinically suitable non-genital vitiligo lesion for dermoscopic imaging.

Descrição

Inclusion Criteria:

  • Adults aged 18 years or older
  • Clinical diagnosis of vitiligo
  • Presence of at least one clinically suitable non-genital vitiligo lesion for dermoscopic imaging
  • Ability and willingness to provide written informed consent

Exclusion Criteria:

  • Uncertain clinical diagnosis of vitiligo or presence of another hypopigmented or depigmented disorder that may interfere with lesion evaluation
  • Absence of any clinically suitable non-genital vitiligo lesion for imaging
  • Inability to cooperate with the imaging procedure
  • Refusal or inability to provide written informed consent

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Modelos de observação: CASE_ONLY
  • Perspectivas de Tempo: CROSS_SECTIONAL

Coortes e Intervenções

Grupo / Coorte
Adults With Vitiligo

Adult participants with clinically diagnosed vitiligo who will undergo close-up dermoscopic imaging of one to three clinically suitable vitiligo lesions during a single study visit

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Comparison of total visibility scores between polarized dermoscopy and sub-ultraviolet reflectance dermoscopy
Prazo: Day 1

For each participant, the index lesion will be evaluated in polarized dermoscopy and sub-ultraviolet reflectance dermoscopy images. Selected lesion morphology items on the finalized scoring form will be scored from 0 to 3, where 0 indicates absent or not visible and 3 indicates clearly visible. A total visibility score will be calculated for each modality, and the paired within-lesion difference between the two modalities will be analyzed.

Day 1

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
Visibility scores of individual lesion morphology items across imaging modalities
Prazo: Day 1

Individual lesion morphology items on the finalized scoring form will be evaluated using a 0-3 visibility scoring system, where 0 indicates absent or not visible and 3 indicates clearly visible. Scores will be assessed across polarized dermoscopy, sub-ultraviolet reflectance dermoscopy, and ultraviolet fluorescence dermoscopy.

Day 1
Detection rates of individual lesion morphology items after dichotomization of visibility scores
Prazo: Day 1

Visibility scores will be dichotomized for each lesion morphology item, with a score of 0 defined as not detected and scores of 1, 2, or 3 defined as detected. Detection rates will be calculated and compared across imaging modalities.

Day 1
Assessment of ultraviolet and sub-ultraviolet optical findings
Prazo: Day 1

Optical findings observed in sub-ultraviolet reflectance dermoscopy and ultraviolet fluorescence dermoscopy will be assessed using the finalized scoring form. Depending on the finalized assessment item, findings may be recorded either as 0-3 visibility scores or as binary detection variables. These findings may include lesion-to-surrounding skin contrast, border visibility, perifollicular optical changes, and intralesional heterogeneity.

Day 1
Inter-rater agreement for lesion morphology assessment
Prazo: Through completion of image evaluation, up to 6 months

Agreement between dermatologist evaluators will be assessed for visibility scores and/or binary detection of lesion morphology items using appropriate agreement statistics.

Through completion of image evaluation, up to 6 months

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Patrocinador

Investigadores

  • Cadeira de estudo: Ayşe Esra Koku Aksu, Professor, University of Health Sciences Istanbul Training and Research Hospital, Dermatology Department

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Real)

1 de julho de 2026

Conclusão Primária (Estimado)

1 de dezembro de 2026

Conclusão do estudo (Estimado)

1 de dezembro de 2026

Datas de inscrição no estudo

Enviado pela primeira vez

23 de setembro de 2026

Enviado pela primeira vez que atendeu aos critérios de CQ

28 de setembro de 2026

Primeira postagem (Real)

29 de setembro de 2026

Atualizações de registro de estudo

Última Atualização Postada (Real)

29 de setembro de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

28 de setembro de 2026

Última verificação

1 de setembro de 2026

Mais Informações

Termos relacionados a este estudo

Outros números de identificação do estudo

  • IstanbulTRH-DERM-VITSUV-2026

Plano para dados de participantes individuais (IPD)

Planeja compartilhar dados de participantes individuais (IPD)?

NÃO

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Não

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .